BioSpace News Archive

Exclusive artwork banner creative collage of hands hold alarm clock deadline payment limit dollar bag exchange finance earnings.

Patents

Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line

Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.

February 24, 2026

·

3 min read

·

Annalee Armstrong

Medical waste concept, Open garbage full of pills, syringes, bandages, masks, protective gloves. Utilization and storage of hospital waste, copy space

Opinion

Cut Down on Oncology Drug Waste With Better Forecasting

Billions of dollars’ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste. A data-driven approach offers a practical path to greater efficiency.

February 24, 2026

·

5 min read

·

Vikas Mahajan

Top view of road and highway junction, intersections and overpasses in vector illustration. Modern roads and transport concept.

Manufacturing

Radiopharmaceutical Sector Shapes Supply Chain Around Fast-Decaying Products

The necessity of delivering medicine days after it’s produced drives decisions about where to build facilities and how to ship radioactive materials to healthcare providers.

February 24, 2026

·

3 min read

·

Nick Paul Taylor

Manual worker with protective work gloves holding a yellow safety helmet on a yellow and orange background with copy space and reflections. Concept of workplace security.

Manufacturing

AbbVie Backs Obesity Push With $380M API Production Expansion Project in Illinois

Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ingredients for next-generation neuroscience and obesity drugs when they start operations in 2029.

February 24, 2026

·

2 min read

·

Nick Paul Taylor

Contemporary art collage. Purple hand holding fan of dollar bills against bright yellow background. stock photo

Collaboration

Astellas Bets up to $1.7B for Vir’s ‘Robust Competitor’ in Prostate Cancer

In a Phase 1 study, 82% of patients on VIR-5500 achieved at least a 50% reduction in PSA levels—a result analysts praised as competitive in the prostate cancer space.

February 24, 2026

·

2 min read

·

Tristan Manalac

GLP-1

Pfizer Builds Global GLP-1 Strategy With up to $495M Sciwind Deal

Ecnoglutide, which Pfizer licensed from Sciwind Biosciences, is already approved in China for type 2 diabetes mellitus, and a marketing application for weight loss has been accepted by regulatory authorities in the country.

February 24, 2026

·

2 min read

·

Tristan Manalac

Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.

Cardiovascular disease

Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty

Following a disappointing Phase 3 performance and given Gossamer Bio’s balance sheet, seralutinib’s path to the market for pulmonary arterial hypertension has become unclear, according to analysts at Guggenheim Partners.

February 24, 2026

·

2 min read

·

Tristan Manalac

Illustration of businessmen running on a track. A man in red is ahead while a man in blue is behind and falling to the track.

Editorial

Novo Returns to Pre-Wegovy Valuation as Lilly Makes History as First Ever $1T Pharma

Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion valuation. It seems one company can do no right, while the other can do no wrong.

February 24, 2026

·

3 min read

·

Jef Akst

Drug pricing

Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss

Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as much as 50%, while boasting Phase 2 data for its invesigational triple-G agonist.

February 24, 2026

·

3 min read

·

Jef Akst

screenshot of Marty Makary speaking on the Megyn Kelly Show

Vaccines

FDA’s Makary Backs mRNA Vaccines but Says Companies ‘Can Fund Their Own Research’

In August last year, the Health Department cut around $500 million in mRNA research funding, with Health Secretary Robert F. Kennedy Jr. saying the agency would instead divert the money “toward safer, broader vaccine platforms.”

February 24, 2026

·

2 min read

·

Tristan Manalac